Respirerx Pharmaceuticals Inc Share Price Other OTC
Equities
US2205243007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2021 | - | Sales 2022 | - | Capitalization | 289K 24.12M |
---|---|---|---|---|---|
Net income 2021 | -3M -251M | Net income 2022 | -2M -167M | EV / Sales 2021 | - |
Net Debt 2021 | 2.08M 173M | Net Debt 2022 | 2.71M 226M | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.29
x | P/E ratio 2022 |
-0.06
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.37% |
Managers | Title | Age | Since |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22/13/22 |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22/13/22 |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 15/14/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22/13/22 |
Director/Board Member | - | 22/23/22 | |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22/13/22 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |